Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First-Line Treatment Options

The American Academy of Neurology recommends pulse methylprednisolone 1g IV daily for 3-5 days for severe or progressing symptoms, followed by a taper over at least 4-6 weeks 1
Oral corticosteroids alone or with immunosuppressive therapy achieve 60-75% response rates in peripheral neuropathies, according to the European League Against Rheumatism 2, 3
Standard dosing of intravenous immunoglobulin (IVIG) is 2g/kg administered over 5 days, as recommended by the American College of Physicians 1
For severe cases with acute inflammatory demyelinating polyneuropathy-type presentation, consider combining pulse corticosteroids PLUS IVIG, as suggested by the National Comprehensive Cancer Network 1, 4
Plasma exchange is an established first-line option, particularly effective in severe cases, according to the American Society for Apheresis 3
Important caveat: Plasmapheresis immediately after IVIG will remove immunoglobulin, so timing must be carefully considered, as noted by the American College of Physicians 5

For mild to moderate disease, initiate oral corticosteroids (prednisone 1 mg/kg daily) with gradual taper over 4-6 weeks, as recommended by the American College of Physicians 1
For severe or rapidly progressive disease, consider pulse methylprednisolone 1g IV daily for 3-5 days PLUS IVIG 2g/kg over 5 days, as suggested by the American College of Physicians 1
Hospital admission is warranted for severe symptoms with functional impairment, according to the American College of Physicians 1

Rituximab should be considered in consultation for patients with limited or no improvement after first-line therapy, as recommended by the European League Against Rheumatism 3, 1
Other immunosuppressants include methotrexate, azathioprine, or mycophenolate mofetil for maintenance therapy or when symptoms do not resolve after 4 weeks, as suggested by the American College of Physicians 1, 5

Nerve conduction studies demonstrating demyelinating features are necessary for diagnosis, according to the American Academy of Physical Medicine and Rehabilitation 6
Exclusion of CNS involvement through neuroimaging is required when focal signs, gait disturbance, or increased reflexes are present, as recommended by the European League Against Rheumatism 2, 3

Approximately 6-10% of patients experience treatment-related fluctuations (TRFs), defined as disease progression within 2 months following initial treatment-induced improvement, according to Nature Reviews Neurology 7
Repeat the full course of IVIG or plasma exchange for TRFs, as this indicates the treatment effect has worn off while inflammation persists, as suggested by Nature Reviews Neurology 7

Do not delay treatment beyond 2 weeks, as this is associated with severe neurological deficit and poor outcomes, according to the European League Against Rheumatism 3
Do not perform plasmapheresis immediately after IVIG administration, as it removes the therapeutic immunoglobulin, as noted by the American College of Physicians 5
Do not assume treatment failure if progression continues in the first 4 weeks—40% of patients do not improve initially but may still benefit from therapy, according to Nature Reviews Neurology 7

Demyelinating neuropathies are classified primarily by their time course: acute forms (Guillain-Barré syndrome and variants) progress over days to 4 weeks, while chronic forms (CIDP and variants) progress beyond 2 months, according to the American Academy of Neurology 8, 9

The American Academy of Neurology states that acute inflammatory demyelinating polyneuropathy (AIDP) is the most common GBS subtype in Western countries, characterized by macrophage-mediated demyelination with lymphocytic infiltration 10, 11
AIDP presents with progressive bilateral ascending weakness affecting limbs initially, potentially progressing to cranial and respiratory muscles, as described by the European Academy of Neurology 10
The American College of Physicians recommends that absent or decreased tendon reflexes in affected limbs at some point during the clinical course are required for diagnosis 8

The American Academy of Neurology indicates that progression beyond 2 months is the key distinguishing feature from GBS, and classic CIDP presents with progressive bilateral weakness with areflexia 8, 9
Cerebrospinal fluid shows cytoalbuminologic dissociation (elevated protein with normal cell count) in CIDP, according to the American Academy of Neurology 8, 9
Electrophysiological studies demonstrate demyelinating features in CIDP, as stated by the American Association of Neuromuscular and Electrodiagnostic Medicine 8, 9

The American Academy of Neurology recommends pulse corticosteroids (methylprednisolone 1g IV daily for 3-5 days) PLUS IVIG 2g/kg over 5 days (0.4 g/kg/day) for severe or progressing symptoms in CIDP 12, 9
Rituximab may be considered in consultation for limited improvement in refractory cases, according to the American College of Rheumatology 12, 9

The European Hematology Association states that 50% of patients with IgM MGUS and peripheral neuropathy have anti-myelin-associated glycoprotein (MAG) antibodies 13
Rituximab is effective in part of patients with IgM neuropathy, as described by the European Neurological Society 13

The American Academy of Neurology recommends establishing the time course of the disease, with days to 4 weeks suggesting GBS spectrum and beyond 2 months suggesting CIDP spectrum 8, 9
Confirming clinical features, including progressive bilateral weakness with areflexia, is required for diagnosis, according to the American College of Physicians 8
Obtaining CSF analysis and performing nerve conduction studies are essential steps in the diagnostic algorithm, as stated by the American Association of Neuromuscular and Electrodiagnostic Medicine 8, 11